Pharma Mar Leads an Oncology Project with a Funding of €3.5 Million

Pharma Mar continues to bet on oncology. The Spanish pharmaceutical company leads the Oncoliberyx project, which brings together four Spanish research groups specialized in nanotechnology and oncology in order to achieve unique formulations that can give rise to new cancer therapies based on marine compounds from the Pharma Mar collection. The project, approved by the Ministry of Science and Innovation, has a financing of €3.49 million with funds from the Recovery, Transformation, and Resilience Plan.

The consortium has the experience and knowledge of leading Spanish researchers in the field of new drug delivery systems, immunotherapy, and cancer, such as professors María José Alonso (University of Santiago de Compostela), María Blanco Prieto (University of Navarra ), Ignacio Melero (Cima University of Navarra) and José Luis Pedraz (University of the Basque Country).

Oncoliberyx focuses on the search for new drug delivery strategies in order to increase the specificity of oncological active compounds, reducing their toxicity and side effects, while maintaining and increasing their therapeutic effects.

Discover the world’s most interesting financial news with the mobile app Born2Invest. The app provides its readers access to the latest news in global business, stock market, finance news, and also trending topics like bitcoin, cryptocurrency, and biotech.

Pharma Mar recorded revenues of €141.4 million in the first three quarters of the year

Currently, cancer is the second leading cause of death in developed Western countries. Despite notable advances in elucidating the biological mechanisms underlying this disease and new therapeutic approaches, concern about the side effects caused by these drugs is driving the search for more selective and effective regimens and therapeutic formulations.

Pharma Mar is a pharmaceutical company focused on the research and development of new cancer treatments. The company has developed and currently markets Yondelis in Europe, as well as Zepzelca (lurbinectedin) in the United States; and Aplidin (plitidepsin), in Australia, with different partners.

Pharma Mar has other programs in the clinical development phase for various types of solid tumors: lurbinectedin, and ecubectedin. Headquartered in Madrid, the group has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland, and the United States. Pharma Mar also has the majority stake in Sylentis, dedicated to researching the therapeutic applications of gene silencing (RNAi).

The Spanish pharmaceutical registered revenues of €141.4 million in the first three quarters of the year, compared to the €140.3 million registered a year ago, which represents a slight increase of 1%.

__

(Featured image by felixioncool via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.